NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $20.12 +0.06 (+0.29%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Denali Therapeutics Stock (NASDAQ:DNLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$19.90▼$20.6550-Day Range$20.06▼$27.2152-Week Range$12.58▼$27.30Volume649,337 shsAverage Volume1.69 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/APrice Target$35.85Consensus RatingModerate Buy Company Overview Denali Therapeutics Inc. is a biotechnology company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company is headquartered in South San Francisco, California, and was founded in 2013 by a team that included Chief Executive Officer Ryan Watts. Denali’s research is built around its blood-brain barrier transport technologies, which are designed to help therapeutic molecules reach the brain. The company applies these technologies to potential treatments for conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, lysosomal storage disorders and other neurodegenerative diseases. Its pipeline has included investigational therapies directed at targets such as LRRK2, TREM2 and RIPK1, as well as enzyme-replacement approaches intended to improve delivery of treatments to the central nervous system. Denali conducts research and clinical development through its operations in the United States and collaborations with pharmaceutical companies, supporting the development of therapies for patients in international markets.AI Generated. May Contain Errors. Read More Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreDNLI MarketRank™: Denali Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 168th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialDenali Therapeutics has a consensus price target of $35.85, representing about 77.9% upside from its current price of $20.16.Amount of Analyst CoverageDenali Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Denali Therapeutics are expected to grow in the coming year, from ($2.67) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.53% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 7.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.23 News SentimentDenali Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Denali Therapeutics this week, compared to 4 articles on an average week.Search Interest7 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows3 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $136,507.00 in company stock.Percentage Held by Insiders9.70% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNLI Stock News HeadlinesDenali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14 at 8:00 PM | seekingalpha.comDenali Therapeutics Inc. (DNLI) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 17 at 1:00 AM | Weiss Ratings (Ad)Denali Therapeutics (NASDAQ:DNLI) Insider Sells $64,881.92 in StockSeptember 4, 2026 | insidertrades.comDenali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term UpsideAugust 20, 2026 | tipranks.comDenali Therapeutics: Bullish On Avlayah And Their ProspectsAugust 19, 2026 | seekingalpha.comDenali Therapeutics (DNLI) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comDenali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial OneAugust 13, 2026 | seekingalpha.comSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $16.51 on January 1st, 2026. Since then, DNLI stock has increased by 22.1% and is now trading at $20.1550. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.17. The firm earned $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. Read the conference call transcript. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $250 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 13,888,888 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' top institutional investors include BlackRock Inc. (8.84%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.98%), Bank of America Corp DE (0.77%) and ADAR1 Capital Management LLC (0.64%). Insiders that own company stock include Ryan J Watts, Alexander O Schuth, Carole Ho, Vicki L Sato and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/17/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DNLI's financial health is in the Green zone, according to TradeSmith. DNLI has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(650) 866-8547FaxN/AEmployees507Year Founded2015Price Target and Rating Average Price Target for Denali Therapeutics$35.85 High Price Target$42.00 Low Price Target$26.00 Potential Upside/Downside+78.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$512.54 million Net MarginsN/A Pretax Margin-14,188.37% Return on Equity-55.27% Return on Assets-44.24% Debt Debt-to-Equity Ratio0.01 Current Ratio8.37 Quick Ratio8.32 Sales & Book Value Annual Sales$330.53 million Price / Sales9.73 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book2.91Miscellaneous Outstanding Shares159,850,000Free Float144,342,000Market Cap$3.22 billion OptionableOptionable Beta1.01 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DNLI) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
